SCHEMBL21725645

SCHEMBL21725645

CC(C)N1CCC[C@H]1c1cccc(F)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 1/20 0.54
MAOB P27338 2/20 0.44
MAOA P21397 1/20 0.44
TSHR P16473 1/20 0.43
GRIA4 P48058 1/20 0.41
JAK2 O60674 3/20 0.41
NTRK1 P04629 3/20 0.41
INSR P06213 1/20 0.41
LYN P07948 1/20 0.41
RET P07949 1/20 0.41
MET P08581 1/20 0.41
ROS1 P08922 1/20 0.41
FGR P09769 1/20 0.41
KIT P10721 1/20 0.41
FGFR4 P22455 1/20 0.41
FGFR3 P22607 1/20 0.41
TIE1 P35590 1/20 0.41
KDR P35968 1/20 0.41
FLT3 P36888 1/20 0.41
NTRK3 Q16288 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4100913 1.00 RIPK1 (0.54) RIPK1MAOBMAOATSHRGRIA4
SCHEMBL4106406 0.95 RIPK1 (0.50) RIPK1MAOBMAOATSHRGRIA4
SCHEMBL4096387 0.91 RIPK1 (0.47) RIPK1MAOBMAOATSHRGRIA4
SCHEMBL21725646 0.86 RIPK1 (0.50) RIPK1MAOBMAOATSHRGRIA4
SCHEMBL27962870 0.85 RIPK1 (0.52) RIPK1MAOBMAOATSHRGRIA4
SCHEMBL23449295 0.84 DRD2 (0.44) RIPK1PIK3C3
SCHEMBL27111350 0.83 DRD2 (0.46) MAOBMAOA
SCHEMBL24775490 0.83 DRD2 (0.46) MAOBMAOA
SCHEMBL19862549 0.82 MAPK1 (0.45) MAOBMAOATSHR
SCHEMBL27745228 0.82 RIPK1 (0.49) RIPK1MAOBMAOATSHRGRIA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11566015-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2023-01-31 US disclosed
US-20210238164-A1 MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2021-08-05 US disclosed
US-10981894-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2021-04-20 US disclosed
US-20200216415-A1 MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2020-07-09 US disclosed
US-10562884-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2020-02-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11566015-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof MC3R, MC1R, MC2R RIPK1 4491/4885MAOB 370/4885MAOA 391/4885
US-20210238164-A1 MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF MC3R, MC1R, MC2R RIPK1 4491/4885MAOB 370/4885MAOA 391/4885
US-10562884-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof MC3R, MC1R, MC2R RIPK1 4491/4885MAOB 370/4885MAOA 391/4885
US-20200216415-A1 MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF MC3R, MC1R, MC2R RIPK1 4491/4885MAOB 370/4885MAOA 391/4885
US-10981894-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof MC3R, MC1R, MC2R RIPK1 4491/4885MAOB 370/4885MAOA 391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.